# EDGAR Filing Document

**Accession Number:** 0001966949
**File Stem:** 0001944048-25-000226
**Filing Date:** 2025-12
**Character Count:** 9557
**Document Hash:** 4135aa7b23558bc7e63dce3aa143087a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001944048-25-000226.hdr.sgml**: 20251217

**ACCESSION NUMBER**: 0001944048-25-000226

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251215

**FILED AS OF DATE**: 20251217

**DATE AS OF CHANGE**: 20251217

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Tillett Caroline
- **CENTRAL INDEX KEY:** 0001966949

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41697
- **FILM NUMBER:** 251580456

**MAIL ADDRESS:**
- **STREET 1:** 199 GRANDVIEW ROAD
- **CITY:** SKILLMAN
- **STATE:** NJ
- **ZIP:** 08558

**FORMER NAME:**
- **FORMER CONFORMED NAME:** Tillet Caroline
- **DATE OF NAME CHANGE:** 20230223
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kenvue Inc.
- **CENTRAL INDEX KEY:** 0001944048
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 881032011
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1228

**BUSINESS ADDRESS:**
- **STREET 1:** 1 KENVUE WAY
- **CITY:** SUMMIT
- **STATE:** NJ
- **ZIP:** 07901
- **BUSINESS PHONE:** 908-874-1200

**MAIL ADDRESS:**
- **STREET 1:** 1 KENVUE WAY
- **CITY:** SUMMIT
- **STATE:** NJ
- **ZIP:** 07901

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** JNTL, Inc.
- **DATE OF NAME CHANGE:** 20220825

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Tillett Caroline<br><sub>(Last) (First) (Middle)</sub><br>1 KENVUE WAY<br><sub>(Street)</sub><br>SUMMIT, NJ 07901<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-12-15 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Scientific Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Kenvue Inc. [ KVUE ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-12-15 |  | M |  | 23158 | A | $0 | 68037.51 | D |  |
| Common Stock | 2025-12-15 |  | F |  | 11846<sup>(1)</sup> | D | $17.28 | 56191.51 | D |  |
| Common Stock | 2025-12-15 |  | M |  | 2994 | A | $0 | 59185.51 | D |  |
| Common Stock | 2025-12-15 |  | F |  | 1532<sup>(1)</sup> | D | $17.28 | 57653.51 | D |  |
| Common Stock | 2025-12-15 |  | M |  | 4399.06 | A | $0 | 62052.57 | D |  |
| Common Stock | 2025-12-15 |  | F |  | 2251<sup>(1)</sup> | D | $17.21 | 59801.57 | D |  |
| Common Stock | 2025-12-15 |  | M |  | 3371.58 | A | $0 | 63173.15 | D |  |
| Common Stock | 2025-12-15 |  | F |  | 1725<sup>(1)</sup> | D | $17.21 | 61448.15 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units<sup>(2)</sup> | <sup>(2)</sup> | 2025-12-15 |  | M |  |  | 23158 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 23158<sup>(4)</sup> | $0 | 0 | D |  |
| Restricted Stock Units<sup>(5)</sup> | <sup>(5)</sup> | 2025-12-15 |  | M |  |  | 2994 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 2994<sup>(4)</sup> | $0 | 0 | D |  |
| Restricted Stock Units | <sup>(7)</sup> | 2025-12-15 |  | M |  |  | 4399.06 | <sup>(8)</sup> | <sup>(8)</sup> | Common Stock | 4399.06<sup>(4)</sup> | $0 | 4399.16<sup>(9)</sup> | D |  |
| Restricted Stock Units | <sup>(7)</sup> | 2025-12-15 |  | M |  |  | 3371.58 | <sup>(10)</sup> | <sup>(10)</sup> | Common Stock | 3371.58<sup>(4)</sup> | $0 | 6740.09<sup>(9)</sup> | D |  |

---

### Footnotes:

(1) Shares withheld for payment of taxes upon vesting of Restricted Stock Units ("RSUs").

(2) These RSUs were originally granted by Johnson & Johnson as performance share units and, in connection with the Issuer's separation from Johnson & Johnson on August 23, 2023, were converted into time-based RSUs with respect to Issuer common stock with adjustments made to the number of shares subject to the award in order to preserve the award's value and with performance criteria deemed satisfied at the target level.

(3) This award was scheduled to vest in full on 02/13/2026, subject to the reporting person's continued service through the vesting date but vesting was accelerated in order to mitigate the adverse impact to the Issuer and the Reporting Person of Section 280G of the Internal Revenue Code in connection with the pending transaction between the Issuer and Kimberly-Clark Corporation ("Section 280G Mitigation").

(4) This award will be subject to clawback in the event it is determined that the Reporting Person would not have ultimately vested in the award notwithstanding the acceleration reflected herein.

(5) These RSUs were originally granted by Johnson & Johnson and, in connection with the Issuer's separation from Johnson & Johnson on August 23, 20223 and pursuant to the terms of the Employee Matters Agreement, dated as of May 3, 2023 between Johnson & Johnson and the Issuer, were converted into RSUs with respect to Issuer common stock with adjustments made to the number of shares subject to the award in order to preserve the award's value.

(6) This award was scheduled to vest in three equal installments on 02/13/2024, 02/13/2025, and 02/13/2026, subject to the reporting person's continued service through the vesting date but the vesting of the portion reflected herein was accelerated from 02/13/2026 in connection with the Section 280G Mitigation.

(7) These units correspond 1 for 1 with the Company's common stock.

(8) This award was scheduled to vest in three equal installments on 03/05/2025, 03/05/2026, and 03/05/2027, subject to the reporting person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated from 03/05/2026 in connection with the 280G Mitigation.

(9) Includes RSUs acquired as dividend equivalents.

(10) This award was scheduled to vest in three equal installments on 03/10/2026, 03/10/2027, and 03/10/2028, subject to the reporting person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated from 03/10/2026 in connection with the Section 280G Mitigation.

**Signature:** /s/ Alla Berenshteyn, as attorney-in-fact  
**Date:** 2025-12-17

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**